Clinical Trial Update: Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating safety, tolerability, and immunogenicity of V419 in healthy infants at 2, 4, and 11–12 months; completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bacterial Infections
• Virus Diseases

Drugs mentioned

• V419

Snippet

Sponsor: MCM Vaccines B.V. | Conditions: Bacterial Infections, Virus Diseases | Phase 3 | Status: COMPLETED | Results posted: 2019-04-02